Posts

Posted on

NNOX INVESTOR REMINDER: Nano-X Imaging Ltd. Investors Have Until August 11, 2026To Seek Lead Plaintiff Role

NNOX INVESTOR REMINDER: Nano-X Imaging Ltd. Investors Have Until August 11, 2026To Seek Lead Plaintiff Role

NEW YORK–(BUSINESS WIRE)–If you have suffered a loss on your Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ:NNOX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Investors have until August 11, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of March 31, 2025 through April 17, 2026, inclusive (“the Class Period”). The lawsuit alleges that (i) Nano-X overstated purported efficiency gains achieved in its operations, as well as the purported increased demand for its products; (ii) in reality, Nano-X’s production and manufacturing operations were poorly aligned with demand for the Company’s products; (iii) as a result, Nano-X was experiencing significantly increased operating expenses and cash burn; and (iv) the foregoing significantly increased the likelihood that Nano-X would be forced to take disruptive remedial measures with respect to its manufacturing operations, entailing significant restructuring and impairment charges.

On April 20, 2026, Nano-X issued a press release announcing its Q4 2025 financial results and business updates. Nano-X reported, inter alia, a Q4 net loss of $33.4 million, mainly due to a $17.5 million charge attributed to impairment of long-lived assets following a restructuring initiative at its Korean chip manufacturing facility. In explaining the restructuring charge, the press release acknowledged that Nano-X needed to “shift[] to a more efficient outsourced production model that is better aligned with current and anticipated demand.” The same press release also announced that Nano-X’s then-Chief Financial Officer (“CFO”), Ran Daniel, would step down as CFO, effective July 31, 2026. The same day, during a related earnings call to discuss these results, Nano-X’s Chief Executive Officer, Erez Meltzer, likewise disclosed that Defendants needed “to reduce our Korean operation’s OpEx [operating expenses] and cash burn and improve efficiency”, while reiterating the need to “transition to a more efficient outsourced production model better aligned with current and projected demand.” On this news, the price of Nano-X shares declined by $0.70 per share, or approximately 25%, from $2.85 per share on April 17, 2026 to close at $2.15 on April 20, 2026.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Nano-X securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

VRRM INVESTOR REMINDER: Verra Mobility Corporation Investors Have Until August 4, 2026To Seek Lead Plaintiff Role

VRRM INVESTOR REMINDER: Verra Mobility Corporation Investors Have Until August 4, 2026To Seek Lead Plaintiff Role

NEW YORK–(BUSINESS WIRE)–If you have suffered a loss on your Verra Mobility Corporation (“Verra Mobility” or the “Company”) (NASDAQ:VRRM) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Investors have until August 4, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of February 24, 2026 through May 26, 2026, inclusive (“the Class Period”). The lawsuit alleges that the Company provided materially false and misleading statements and/or concealed material adverse facts concerning the true state of Verra Mobility’s relationship with Avis Budget Group regarding its contract extension with Avis. Further, the Company minimized concerns that major car rental agencies could replace Verra Mobility with in-house solutions or outsourced alternatives.

On May 26, 2026, Verra Mobility announced that it received a termination notice from Avis Budget Group, which becomes effective in September 2026. The Company further disclosed that it “expects the termination to reduce Commercial Services’ 2026 annualized revenue by approximately $135 million to $145 million and 2026 annualized segment profit by approximately $120 million to $125 million, before taking into account expected cost reduction initiatives.” On this news, the price of Verra Mobility shares declined by $9.23 per share, or approximately 71%, from $13.08 per share on May 26, 2026 to close at $3.85 on May 27, 2026.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Verra Mobility securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role

ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role

NEW YORK–(BUSINESS WIRE)–If you have suffered a loss on your Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Investors have until August 10, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of January 14, 2025 through April 26, 2026, inclusive (“the Class Period”). The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015. The company presented ERAS-0015 as a potential “best-in-class” therapy and highlighted purportedly superior preclinical results compared to Revolution Medicines’ competing drug candidate, RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposing the Company to patent and trade secret disputes, and lacked a reasonable basis.

On April 27, 2026, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for RevMed alleging that Erasca’s ERAS-0015 infringes a RevMed patent (U.S. Patent No. 12,409,225) and is connected to alleged trade secret misappropriation. RevMed also alleged that Erasca had “improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures” and demanded Erasca cease making “deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236.” Erasca stated that it believes the assertions are without merit and intends to contest the allegations. On this news, the price of Erasca shares declined by $2.34 per share, or approximately 11%, from $21.49 per share on April 24, 2026 to close at $19.15 on April 27, 2026.

On April 27, 2026, Erasca filed a separate Form 8-K reporting preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015. The patient was classified as a “Grade 3 TRAE of pneumonitis” that “progressed to Grade 5 after withdrawal of supportive care per patient decision.” Erasca further stated that comparisons between ERAS-0015 and other product candidates, including RMC-6236, were based on cross-study analyses and “not based on any head-to-head clinical trials,” and that such comparisons are “inherently limited and such data may not be directly comparable.” On this news, the price of Erasca shares declined by $9.25 per share, or approximately 48%, from $19.15 per share on April 27, 2026 to close at $9.90 on April 28, 2026.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Erasca securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

Sun Life cautions shareholders regarding Ocehan LLC’s below-market bid for shares

PR Newswire

Sun Life logo

TORONTO, July 3, 2026 /PRNewswire/ – Sun Life Financial Inc. (“Sun Life”) (TSX: SLF) (NYSE: SLF) has been notified that Ocehan LLC (“Ocehan”) has made an unsolicited mini-tender offer to purchase up to 100,000 common shares of Sun Life.

Sun Life is not associated with Ocehan and does not recommend or endorse acceptance of Ocehan’s unsolicited offer. Shareholders are not required to sell their shares to Ocehan.

Sun Life cautions that Ocehan’s mini-tender offer has been made at a price that is significantly lower than recent market prices for Sun Life common shares. This offer represents a discount of 24.95% and 24.38%, respectively, to the closing prices of Sun Life’s common shares on the TSX on May 25, 2026 and the NYSE on May 22, 2026, the last trading day before the mini-tender offer was commenced.

About Mini-Tender Offers
Securities administrators in Canada and the United States recommend that investors exercise caution with mini-tender offers. Mini-tender offers are designed to avoid disclosure and procedural requirements applicable to most bids under applicable Canadian and U.S. securities laws. Canadian Securities Administrators (“CSA”) and the U.S. Securities and Exchange Commission (“SEC”) have expressed serious concerns about mini-tender offers, including the possibility that investors might tender to such offers without understanding the offer price relative to the actual market price of their securities.

The SEC has indicated that “bidders make mini-tender offers at below-market prices, hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” The SEC has issued “Tips for Investors” regarding mini-tender offers. The SEC’s advisory can be found on its website at: www.sec.gov/investor/pubs/minitend.htm.

Information on the CSA’s long-standing guidance on mini-tenders can be found on the Ontario Securities Commission website at: www.osc.ca/en/securities-law/instruments-rules-policies/6/61-301/csa-staff-notice-61-301-staff-guidance-practice-mini-tenders.

Brokers, dealers and other market participants are encouraged to exercise caution and review the letter regarding broker-dealer mini-tender offer dissemination and disclosures on the SEC website at: www.sec.gov/divisions/marketreg/minitenders/sia072401.htm.

Sun Life requests that a copy of this news release be included in any distribution of materials relating to Ocehan’s mini-tender offer for Sun Life common shares.

Information for Sun Life Shareholders
According to Ocehan’s offer documents, Sun Life shareholders who have already tendered their shares can withdraw their shares within 21 days in accordance with the procedures set forth in the offer documents.

Shareholders should carefully review the Ocehan offer documents, consult with their Sun Life advisor or investment advisor to discuss any offer they may receive and review all options they have for their investment in Sun Life shares. If you are in Canada and do not have a Sun Life advisor and are interested in finding one, please visit www.sunlife.ca/en/find-an-advisor/.

Sun Life Resources
Sun Life has stock transfer agents providing shareholder services in Canada, the United States, the United Kingdom, Hong Kong and the Philippines. These local agents provide services directly to our registered shareholders and can provide information on share account management, direct deposit of dividends, dividend reinvestment and share purchase plans. Please email [email protected] or call 1-877-224-1760 for more information.

About Sun Life

Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of March 31, 2026, Sun Life had total assets under management of $1.58 trillion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Note to editors: All figures in Canadian dollars.

To contact Sun Life media relations, please email

[email protected]

.

To contact Sun Life investor relations, please email

[email protected]

.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sun-life-cautions-shareholders-regarding-ocehan-llcs-below-market-bid-for-shares-302817757.html

SOURCE Sun Life Financial Inc. – Financial News

Posted on

Sun Life cautions shareholders regarding Ocehan LLC’s below-market bid for shares

Canada NewsWire

Sun Life logo

TORONTO, July 3, 2026 /CNW/ – Sun Life Financial Inc. (“Sun Life”) (TSX: SLF) (NYSE: SLF) has been notified that Ocehan LLC (“Ocehan”) has made an unsolicited mini-tender offer to purchase up to 100,000 common shares of Sun Life.

Sun Life is not associated with Ocehan and does not recommend or endorse acceptance of Ocehan’s unsolicited offer. Shareholders are not required to sell their shares to Ocehan.

Sun Life cautions that Ocehan’s mini-tender offer has been made at a price that is significantly lower than recent market prices for Sun Life common shares. This offer represents a discount of 24.95% and 24.38%, respectively, to the closing prices of Sun Life’s common shares on the TSX on May 25, 2026 and the NYSE on May 22, 2026, the last trading day before the mini-tender offer was commenced.

About Mini-Tender Offers
Securities administrators in Canada and the United States recommend that investors exercise caution with mini-tender offers. Mini-tender offers are designed to avoid disclosure and procedural requirements applicable to most bids under applicable Canadian and U.S. securities laws. Canadian Securities Administrators (“CSA”) and the U.S. Securities and Exchange Commission (“SEC”) have expressed serious concerns about mini-tender offers, including the possibility that investors might tender to such offers without understanding the offer price relative to the actual market price of their securities.

The SEC has indicated that “bidders make mini-tender offers at below-market prices, hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” The SEC has issued “Tips for Investors” regarding mini-tender offers. The SEC’s advisory can be found on its website at: www.sec.gov/investor/pubs/minitend.htm.

Information on the CSA’s long-standing guidance on mini-tenders can be found on the Ontario Securities Commission website at: www.osc.ca/en/securities-law/instruments-rules-policies/6/61-301/csa-staff-notice-61-301-staff-guidance-practice-mini-tenders.

Brokers, dealers and other market participants are encouraged to exercise caution and review the letter regarding broker-dealer mini-tender offer dissemination and disclosures on the SEC website at: www.sec.gov/divisions/marketreg/minitenders/sia072401.htm.

Sun Life requests that a copy of this news release be included in any distribution of materials relating to Ocehan’s mini-tender offer for Sun Life common shares.

Information for Sun Life Shareholders
According to Ocehan’s offer documents, Sun Life shareholders who have already tendered their shares can withdraw their shares within 21 days in accordance with the procedures set forth in the offer documents.

Shareholders should carefully review the Ocehan offer documents, consult with their Sun Life advisor or investment advisor to discuss any offer they may receive and review all options they have for their investment in Sun Life shares. If you are in Canada and do not have a Sun Life advisor and are interested in finding one, please visit www.sunlife.ca/en/find-an-advisor/.

Sun Life Resources
Sun Life has stock transfer agents providing shareholder services in Canada, the United States, the United Kingdom, Hong Kong and the Philippines. These local agents provide services directly to our registered shareholders and can provide information on share account management, direct deposit of dividends, dividend reinvestment and share purchase plans. Please email [email protected] or call 1-877-224-1760 for more information.

About Sun Life

Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of March 31, 2026, Sun Life had total assets under management of $1.58 trillion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Note to editors: All figures in Canadian dollars.

To contact Sun Life media relations, please email

[email protected]

.

To contact Sun Life investor relations, please email

[email protected]

.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sun-life-cautions-shareholders-regarding-ocehan-llcs-below-market-bid-for-shares-302817757.html

SOURCE Sun Life Financial Inc. – Financial News

Posted on

Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08

NEW YORK, July 03, 2026 (GLOBE NEWSWIRE) — Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee.

Effective July 1, 2026, in connection with commencing employment as Head of Product of BetterHelp, David Packles was granted an award of restricted stock units covering 50,000 shares of Teladoc Health’s common stock, par value $0.001 per share (“Common Stock”). The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on the first anniversary of the grant date, with the remainder vesting quarterly over two years thereafter. The award was approved by the Compensation Committee of the Board of Directors of Teladoc Health and was granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as an employment inducement award pursuant to New York Stock Exchange Rule 303A.08.

About Teladoc Health

Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.

Media:

Lou Serio
202-569-9715
[email protected]



Posted on

John Marshall Bancorp, Inc. Announces Second Quarter 2026 Earnings Release Date

John Marshall Bancorp, Inc. Announces Second Quarter 2026 Earnings Release Date

RESTON, Va.–(BUSINESS WIRE)–
John Marshall Bancorp, Inc. (Nasdaq: JMSB) today announced that it expects to issue second quarter 2026 earnings before the market opens on Wednesday, July 22, 2026.

About John Marshall Bancorp, Inc.:

John Marshall Bancorp, Inc. is the bank holding company for John Marshall Bank. The Bank is headquartered in Reston, Virginia with eight full-service branches located in Alexandria, Arlington, Loudoun, Prince William, Reston, and Tysons, Virginia, as well as Rockville, Maryland, and Washington, D.C. The Bank is dedicated to providing exceptional value, personalized service and convenience to local businesses and professionals in the Washington D.C. Metro area. The Bank offers a comprehensive line of sophisticated banking products and services that rival those of the largest banks along with experienced staff to help achieve customers’ financial goals. Dedicated Relationship Managers serve as direct points-of-contact, providing subject matter expertise in a variety of niche industries including Commercial Real Estate, Trade Contractors, Government Contractors, Health Services, Nonprofits, Private & Charter Schools, Professional Services, Property Management, Community Associations, and Title & Escrow Services. Learn more at www.johnmarshallbank.com. Follow the Bank on LinkedIn at: https://www.linkedin.com/company/john-marshall-bank/.

Christopher W. Bergstrom, (703) 584-0840

Kent D. Carstater, (703) 289-5922

KEYWORDS: United States North America District of Columbia Virginia

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, Texas–(BUSINESS WIRE)–
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted six new employees options to purchase an aggregate of 180,350 shares of the Company’s common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance with Nasdaq Listing Rule 5635(c)(4). Options to purchase 157,850 shares were granted to five employees effective June 25, 2026, and options to purchase 22,500 shares were granted to one employee effective June 29, 2026.

The Option Awards granted on June 25, 2026 have an exercise price of $24.67 per share, and the Option Awards granted on June 29, 2026 have an exercise price of $23.22 per share, in each case equal to the closing price of the Company’s common stock on the applicable grant date. The Option Awards will vest, with respect to 25% of the shares subject to each such award, on the first anniversary of the applicable employee’s start date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter, in each case subject to such employee’s continued service with Faeth through each such vesting date.

About Faeth Therapeutics

Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., together with scientific founders Lewis Cantley, Ph.D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph.D.; Scott Lowe, Ph.D.; and Greg Hannon, Ph.D. The Company intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit www.faeththerapeutics.com and follow the Company on LinkedIn.

Investor Contact:

Matthew Biegler, SVP, Investor Relations

[email protected]

Stephanie Ascher, Precision AQ

[email protected]

Media Contact:

Patrick Schmidt, Consort Partners

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo
Logo
Posted on

REE Automotive Announces Receipt of Nasdaq Delisting Notice

TEL AVIV, Israel, July 03, 2026 (GLOBE NEWSWIRE) — REE Automotive Ltd. (Nasdaq: REE) (“REE” or the “Company”), an automotive technology company that develops and builds software-defined vehicle technology, today announced that it has received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that due to the fact that it  has not regained compliance with Nasdaq Listing Rule 5550(a)(2), the Nasdaq staff has determined to delist the Company’s Class A ordinary shares (the “Ordinary Shares”) from The Nasdaq Capital Market (the “Delisting Determination”) and its Ordinary Shares will be suspended from trading on the Nasdaq Capital Market on July 7, 2026.

As previously reported, the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the closing bid price for its Ordinary Shares was below $1.00 per share (the “Minimum Bid Price Requirement”) for 30 consecutive business days beginning on May 15, 2025 through June 27, 2025. On July 1, 2025, Nasdaq notified the Company that the closing bid price of its Ordinary Shares had been below $1.00 for 30 consecutive business days, triggering a deficiency under the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial 180-day period, through December 29, 2025, to regain compliance. On December 30, 2025, Nasdaq determined that REE met all other applicable continued listing criteria and was therefore eligible for an additional 180-day extension, through June 29, 2026, to cure the deficiency. Because the Company has not regained compliance with the Minimum Bid Price Requirement during the additional 180-days compliance period, Nasdaq sent the Delisting Determination on June 30, 2026.

The Company may request a hearing before the Nasdaq Hearings Panel by July 7, 2026, but does not intend to do so. The trading of the Company’s Ordinary Shares will be suspended on the Nasdaq Capital Market at the opening of business on July 7, 2026, and Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq.

About REE Automotive

REE Automotive (Nasdaq: REE) is an automobile technology company that develops and produces cutting edge software-defined vehicle, or SDV, technology that manages vehicle operations and features through proprietarily-developed software, enabling what we believe to be safer, more modular, and better performing vehicles. Our advanced SDV technology utilizes zonal architecture to enhance redundancy and stability and it contains the capabilities for updates and improvements over-the-air throughout an SDV’s lifespan. This makes Powered by REE® vehicles highly adaptable to customer and market changes and our technology is designed in an effort to be future proofed, autonomous capable. As the first company to FMVSS certify a full by-wire vehicle in the U.S., REE’s proprietary by-wire technology for drive, steer and brake control eliminates the need for mechanical connection. Our approach of “complete not compete” allows original equipment manufacturers, or OEMs, and technology companies to license our technology in order to design and build vehicles reliant upon our SDV technology to their specific requirements and needs. To learn more about REE Automotive’s patented technology and unique value proposition that position the Company to break new ground in e-mobility, visit www.ree.auto.

Media Contact

Keren Shemesh
Chief Marketing Officer for REE Automotive
[email protected]

Investor Contact

Hai Aviv
Chief Finance Officer for REE Automotive
[email protected]



Posted on

Commvault Systems (CVLT) Executives Sold $9.4 Million in Stock Amid $1.7 Billion Market Cap Wipeout and Pending Securities Class Action – HBSS

SAN FRANCISCO, July 03, 2026 (GLOBE NEWSWIRE) — On January 27, 2026, investors in Commvault Systems, Inc. (NASDAQ: CVLT) suffered a devastating 31% stock price collapse after the company delivered disappointing quarterly results.

Since this time, company executives have unloaded millions of dollars in personal stock holdings, as the company faces a federal securities class action alleging it misled investors about its growth prospects.

Hagens Berman is investigating the claims pled in the pending suit and encourages Commvault investors who suffered substantial losses to submit your losses now.

Class Period: Apr. 29, 2025 – Jan. 26, 2026
Lead Plaintiff Deadline: July 17, 2026
Visit:www.hbsslaw.com/investor-fraud/cvlt
Contact the Firm Now: [email protected]
                                        844-916-0895
View our latest video summary of the allegations: youtu.be/YILiBV90q2w

Over $9.4 Million in Recent Executive Stock Sales

According to publicly filed insider trading reports, Commvault’s top executives — including its CEO, CFO, and Chief Accounting Officer — have collectively sold over $9.4 million in company shares between February and May 2026:

  • Sanjay Mirchandani, President & CEO — sold approximately 72,874 shares totaling over $7,015,973 across five separate transactions between February and May 2026.
  • Gary Merrill, Chief Financial Officer — sold approximately 20,474 shares totaling over $2,101,458 across four transactions during the same period.
  • Danielle Nicole Abrahamsen, Chief Accounting Officer — sold approximately 2,951 shares totaling over $305,668 across four transactions during the same period.

Commvault Systems, Inc. (CVLT) Securities Class Action:

These insider sales come against the backdrop of a securities class action lawsuit filed on behalf of investors who purchased Commvault securities between April 29, 2025, and January 26, 2026.

The lawsuit alleges Commvault’s class period disclosures violated federal securities laws by creating a misleading impression about the company’s growth trajectory. Specifically, the complaint alleges that during the Class Period, Commvault repeatedly touted that its “execution has never been better across the business,” claimed it would “continue to see hyper-growth within [its] SaaS platform,” and promoted its ARR growth and accelerated SaaS target achievement “two quarters earlier than planned.”

The truth allegedly emerged on January 27, 2026, when Commvault reported Q3 2026 financial results revealing a significant miss in net new ARR, a reduction in full-year ARR growth guidance, and a dramatic deceleration in SaaS ARR year-over-year growth — plunging from 71% to just 40%. The company revealed for the first time that the composition of its sales activity materially impacted ARR, with volumes increasingly coming from dramatically lower-priced SaaS deals and heavily discounted long-term contracts.

Several analysts reportedly characterized the results as a “mess” and questioned Commvault’s ability to execute, promptly downgrading the stock.

HBSS Investigation

“We’re investigating whether Commvault misled investors regarding its ARR growth by masking the impact of lower-priced SaaS deals and heavy discounting, as the complaint alleges,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Commvault and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to frequently asked questions about the Commvault case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Commvault should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895